WO2005123721A3 - Formes amorphes et polymorphes de candesartan cilexetil - Google Patents

Formes amorphes et polymorphes de candesartan cilexetil Download PDF

Info

Publication number
WO2005123721A3
WO2005123721A3 PCT/IB2005/001739 IB2005001739W WO2005123721A3 WO 2005123721 A3 WO2005123721 A3 WO 2005123721A3 IB 2005001739 W IB2005001739 W IB 2005001739W WO 2005123721 A3 WO2005123721 A3 WO 2005123721A3
Authority
WO
WIPO (PCT)
Prior art keywords
candesartan cilexetil
polymorphic forms
amorphous
present
novel polymorphic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/001739
Other languages
English (en)
Other versions
WO2005123721A2 (fr
Inventor
Yatendra Kumar
Shantanu De
Swargam Sathyanarayana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2005123721A2 publication Critical patent/WO2005123721A2/fr
Publication of WO2005123721A3 publication Critical patent/WO2005123721A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une forme amorphe sensiblement pure de candesartan cilexetil. Elle concerne également de nouvelles formes polymorphes de candesartan cilexetil, un procédé de préparation et des compositions pharmaceutiques pour antagoniser l'angiotensine II. Les nouvelles formes polymorphes ont état désignées 'forme A' et 'forme B' de candesartan cilexetil.
PCT/IB2005/001739 2004-06-18 2005-06-20 Formes amorphes et polymorphes de candesartan cilexetil Ceased WO2005123721A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1154DE2004 2004-06-18
IN1154/DEL/2004 2004-06-18
IN1312/DEL/2004 2004-07-16
IN1312DE2004 2004-07-16

Publications (2)

Publication Number Publication Date
WO2005123721A2 WO2005123721A2 (fr) 2005-12-29
WO2005123721A3 true WO2005123721A3 (fr) 2006-06-08

Family

ID=35094269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001739 Ceased WO2005123721A2 (fr) 2004-06-18 2005-06-20 Formes amorphes et polymorphes de candesartan cilexetil

Country Status (1)

Country Link
WO (1) WO2005123721A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7692023B2 (en) 2004-02-11 2010-04-06 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
WO2008035360A2 (fr) * 2006-06-13 2008-03-27 Alembic Limited Nouvelles formes cristallines
KR20090049089A (ko) * 2006-09-05 2009-05-15 아스트라제네카 아베 칸데사르탄 실렉세틸을 포함하는 약학 조성물
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
EP1952806A1 (fr) 2007-02-01 2008-08-06 Helm AG Procédé de préparation des produits d'absorption de candesartan
EP1997479A1 (fr) * 2007-05-31 2008-12-03 Helm AG Formulations stabilisées contentant du candesartan cilexetil amorphe pour l'administration orale

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009057A1 (fr) * 2002-07-18 2004-01-29 Astrazeneca Ab Procede de preparation de dispersions de nanoparticules cristallines
WO2004085426A1 (fr) * 2003-03-27 2004-10-07 Hetero Drugs Limited Nouvelles formes cristallines de candesartan cilexetil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009057A1 (fr) * 2002-07-18 2004-01-29 Astrazeneca Ab Procede de preparation de dispersions de nanoparticules cristallines
WO2004085426A1 (fr) * 2003-03-27 2004-10-07 Hetero Drugs Limited Nouvelles formes cristallines de candesartan cilexetil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIROKAZU MATSUNAGA ET AL: "Solid-state characterization of candesartan cilexetil (TCV-116): crystal structure and molecular mobility", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 47, no. 2, February 1999 (1999-02-01), pages 182 - 186, XP002957606, ISSN: 0009-2363 *

Also Published As

Publication number Publication date
WO2005123721A2 (fr) 2005-12-29

Similar Documents

Publication Publication Date Title
WO2007052289A3 (fr) Nouvelle composition de comprime dispersible
WO2004082822A3 (fr) Procedes permettant d'isoler la forme i cristalline de la 5-azacytidine
WO2006023627A8 (fr) Polymorphes de rapamycine et leurs utilisations
WO2007096151A3 (fr) Composes organiques
WO2008002683A3 (fr) Carvédilol phosphate
WO2008005877A3 (fr) Inhibiteurs de c-kit et leurs utilisations
WO2009025876A3 (fr) Formes cristallines de chlorhydrate d'erlotinib et formulations de celles-ci
WO2008057291A3 (fr) Imatinib base et mésylate d'imatinib et procédés pour la préparation de ceux-ci
WO2006074951A3 (fr) Composition d'olanzapine ou de donepezil a desintegration orale
WO2007001065A3 (fr) Methode pour preparer un produit medicamenteux se presentant sous forme de granules humides
WO2006128150A3 (fr) Formes solides cristallines de tigecycline et procedes de preparation de celles-ci
WO2006035277A3 (fr) Nouvelles methodes de preparation de calcium de rosuvastatine amorphe et nouvelle forme polymorphe de sodium de rosuvastatine
WO2007044950A3 (fr) Formes cristallines de docetaxel et leurs processus de preparation
WO2007098273A3 (fr) Nouvelles formes cristallines d'armodafinil et leur preparation
WO2007131907A3 (fr) Dérivés de 1h-indol-5-yl-pipérazin-1-yl-méthanone
WO2005085236A3 (fr) Inhibiteurs de la caspase et leurs utilisations
WO2005084648A8 (fr) Compositions pharmaceutiques comprenant du candesartan cilexetil
WO2008035360A3 (fr) Nouvelles formes cristallines
WO2004111008A3 (fr) Utilisation d'un compose de formule i pour la preparation d'une composition pharmaceutique
WO2005123721A3 (fr) Formes amorphes et polymorphes de candesartan cilexetil
IL183104A0 (en) Method for production of candesartan
WO2005077941A3 (fr) Polymorphes de candesartan cilexetil
WO2008075163A3 (fr) Procédé perfectionné pour la fabrication de rizatriptan
WO2009019662A3 (fr) Compositions à base de métaxolone orale
WO2009007747A3 (fr) Nouveaux composés

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase